#ASH2424: Mantle cell lymphoma

To update you on the exciting content presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, Dec 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up with our live social media relating to mantle cell lymphoma, here.

CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Tom van Meerten @umcg highlights results from the primary analysis of Cohort 3 from the phase II ZUMA-2 trial.
Brexu-cel demonstrated a high ORR (91%) and CR rate (73%) in pts with R/R MCL who were naive to BTKi, with no new safety signals… pic.twitter.com/kG23xQCxrL

— Lymphoma Hub (@lymphomahub) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Jia Ruan @WeillCornell presents results from a phase II trial of the ALR and ALO regimens in treatment-naïve patients with MCL.
Results demonstrate that the ALR regimen is associated with high rates of durable complete and molecular responses, and… pic.twitter.com/u5S6T1qDvM

— Lymphoma Hub (@lymphomahub) December 9, 2024

CONGRESS #ASH24 | PRESENTATION
Martin Dreyling, LMU University Hospital of Munich presented data from the TRIANGLE trial of ibrutinib-containing 1st line treatment in mantle cell lymphoma. There was no FFS superiority of ASCT + ibrutinib vs ibruitinib alone. Addition of ibrutinib… pic.twitter.com/HDP3GjkATU

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
Nina Wagner-Johnston, @KimmelCancerCtr presented results from the 3-arm ECOG-ACRIN EA4181 trial. Addition of acalabrutinib to the standard treatment arm added toxicity without improvement in efficacy, however when added to just bendamustine and… pic.twitter.com/gmjsS5D76z

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS #ASH24 | PRESENTATION
David Lewis, @UHP_NHS discussed results from the phase II/III ENRICH study, comparing Ibrutinib-Rituximab to Rituximab-Chemotherapy . The PFS with IR was superior to R-chemo. The 5 y OS for IR is 57.7% compared to 54.5% for R-chemo, with QoL at… pic.twitter.com/juCRpgjJ1b

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
David Wald @cwru shares results from a phase I trial of UF-Kure19, an ultra-fast CAR T-cell manufacturing platform, in patients with R/R NHL.
UF-Kure19 demonstrated durable response rates and was well tolerated in patients with NHL.
Follow our… pic.twitter.com/uCL9arDkQF

— Lymphoma Hub (@lymphomahub) December 7, 2024

CONGRESS | #ASH24 | POSTER@elizabeth_budde @CityofHope presented data from a phase II trial of mosunetuzumab monotherapy in patients with heavily pre-treated R/R MCL.
Mosunetuzumab monotherapy demonstrated encouraging activity, with an ORR of 44% and a CR of 24% in patients with… pic.twitter.com/o3PAoIp6ag

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | POSTER
Martin Dreyling, Klinikum der Universitaet Munchen presented high-risk subgroup and MRD analysis outcomes of the phase III ECHO trial of acalabrutinib plus bendamustine (B) and rituximab (R) in untreated MCL.
Acalabrutinib in combination with BR… pic.twitter.com/HRJyUH9vc4

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | POSTER@michaelwangmd, @MDAndersonnews, presented long-term findings from the ZUMA-2 trial (NCT02601313) of brexucabtagene autoleucel (Brexu-cel) in patients with R/R mantle cell #lymphoma. The study assessed in two dose levels: Cohort 1 (2x10^6 cells/kg;… pic.twitter.com/Rp85sBpVdG

— Lymphoma Hub (@lymphomahub) December 11, 2024